Radiological‐pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib

Michael Vouche, Laura Kulik, Rohi Atassi, Khairuddin Memon, Ryan Hickey, Daniel Ganger, Frank H. Miller, Vahid Yaghmai, Michael Abecassis, Talia Baker, Mary Mulcahy, Ritu Nayar, Robert J. Lewandowski, Riad Salem – 22 May 2013 – The aim of this study was to compare radiological and pathological changes and test the adjunct efficacy of Sorafenib to Y90 as a bridge to transplantation in hepatocellular carcinoma (HCC). 15 patients with 16 HCC lesions were randomized to Y90 without (Group A, n = 9) or with Sorafenib (Group B, n = 7).

Signal transducer and activator of transcription 3 is a proviral host factor for hepatitis C virus

Erin M. McCartney, Karla J. Helbig, Sumudu K. Narayana, Nicholas S. Eyre, Amanda L. Aloia, Michael R. Beard – 22 May 2013 – Host factors play an important role in all facets of the hepatitis C virus (HCV) life cycle and one such host factor is signal transducer and activator of transcription 3 (STAT3). The HCV core protein has been shown to directly interact with and activate STAT3, while oxidative stress generated during HCV replication in a replicon‐based model also induced STAT3 activation. However, despite these findings the precise role of STAT3 in the HCV life cycle remains unknown.

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation

Surakit Pungpapong, Bashar A. Aqel, Ludi Koning, Jennifer L. Murphy, Tanisha M. Henry, Kristen L. Ryland, Maria L. Yataco, Raj Satyanarayana, Barry G. Rosser, Hugo E. Vargas, Michael R. Charlton, Andrew P. Keaveny – 21 May 2013 – The safety, efficacy, and effect on immunosuppression levels of telaprevir (TVR) or boceprevir (BOC) in combination with peginterferon (PEG‐IFN) and ribavirin (RBV) in recipients of liver transplantation (LT) with hepatitis C virus (HCV) genotype 1 have not been defined.

Chronic Lithium Treatment Protects Against Liver Ischemia/Reperfusion Injury in Rats

Anding Liu, Haoshu Fang, Uta Dahmen, Olaf Dirsch – 21 May 2013 – Lithium has long been widely used in the treatment of bipolar mood disorders. Recent studies have demonstrated that lithium is able to decrease ischemia/reperfusion (I/R) injury in the brain, kidneys, and heart. Because lithium may act on a number of stress and survival pathways, it is of great interest to explore this compound also in the setting of liver I/R injury. In this study, we aimed to evaluate the effects of lithium in a model of liver I/R injury in rats.

Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography

Dominik Krzanicki, Anita Sugavanam, Susan Mallett – 21 May 2013 – Thrombotic complications are more common in liver disease than might be expected because of the coagulopathy described by conventional coagulation tests. Some of these complications may be life‐threatening. The phenomenon of hypercoagulation is associated with complications in many populations, but the incidence in liver transplant recipients is unclear. We performed a retrospective database review of intraoperative thromboelastography (TEG) for 124 liver transplant recipients.

Acute‐on‐chronic liver failure: Excellent outcomes after liver transplantation but high mortality on the wait list

Armin Finkenstedt, Karin Nachbaur, Heinz Zoller, Michael Joannidis, Johann Pratschke, Ivo W. Graziadei, Wolfgang Vogel – 21 May 2013 – Acute‐on‐chronic liver failure (ACLF) is characterized by high short‐term mortality. Liver transplantation (LT) is a potential therapy for patients who do not improve with supportive measures, but the efficacy of LT has not been shown. The aim of this study was to investigate the feasibility of LT and to determine the postoperative outcomes of patients with ACLF. All patients referred to our liver unit between 2002 and 2010 were registered in a database.

Subscribe to